Holen Sie sich die Stockscreener-App
7.505
14.23%
0.935
Handel nachbörslich:
7.75
0.245
+3.26%
Schlusskurs vom Vortag:
$6.57
Offen:
$6.54
24-Stunden-Volumen:
2.20M
Relative Volume:
2.88
Marktkapitalisierung:
$488.44M
Einnahmen:
$73.48M
Nettoeinkommen (Verlust:
$-108.30M
KGV:
-3.3356
EPS:
-2.25
Netto-Cashflow:
$-67.17M
1W Leistung:
+24.46%
1M Leistung:
+55.38%
6M Leistung:
+19.70%
1J Leistung:
+525.42%
1-Tages-Spanne:
$6.38
$7.52
1-Wochen-Bereich:
$5.875
$7.52
52-Wochen-Spanne:
$1.19
$7.52
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Vergleichen Sie PSNL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
7.505 | 488.44M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
427.76 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
202.50 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
542.71 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.66 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
164.65 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
The 13% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 394% - Yahoo
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Personalis: Ultra-Sensitive Tech, Ultra-Sensitive Risks (NASDAQ:PSNL) - Seeking Alpha
Two Sigma Advisers LP Grows Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Shares Purchased by Two Sigma Investments LP - Defense World
Ameriprise Financial Inc. Has $199,000 Holdings in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Bank of America Corp DE Sells 30,474 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy - MSN
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO - BioSpace
Personalis reveals ctDNA test predicts cervical cancer relapse By Investing.com - Investing.com South Africa
Personalis reveals ctDNA test predicts cervical cancer relapse - Investing.com Australia
Personalis (PSNL) Blood Test Shows Promise in Detecting Cervical Cancer Early | PSNL Stock News - GuruFocus
Personalis Says Studies Show NeXT Personal Test Could Identify Relapse Risk in Breast Cancer Patients - marketscreener.com
Personalis (PSNL) Showcases Promising Results for NeXT Personal in Breast Cancer Care | PSNL Stock News - GuruFocus
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse - Yahoo Finance
Northern Trust Corp Lowers Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Millennium Management LLC Has $7.61 Million Stock Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
BNP Paribas Financial Markets Acquires 71,721 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis and Academic Partners to Present Latest Data on Ultra - GuruFocus
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection - Yahoo Finance
New Clinical Data Reveals Groundbreaking Early Cancer Detection ResultsPersonalis ASCO Preview - Stock Titan
Personalis Holds Virtual Annual Stockholders Meeting - TipRanks
PSNL to Discuss Future Plans in Upcoming Virtual Meeting | PSNL Stock News - GuruFocus
Brokerages Set Personalis, Inc. (NASDAQ:PSNL) PT at $8.00 - Defense World
Personalis Inc (PSNL): A Sitting Duck With -162.63% Upside Potential - Stocksregister
Guggenheim Begins Coverage on Personalis (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Stake Raised by Jane Street Group LLC - Defense World
Jane Street Group LLC Has $2.32 Million Stock Holdings in Personalis, Inc. (NASDAQ:PSNL) - The AM Reporter
Personalis, Inc. (NASDAQ:PSNL) Shares Acquired by Stifel Financial Corp - Defense World
Guggenheim Initiates Buy Rating for Personalis (PSNL) with $6 Ta - GuruFocus
Guggenheim starts Personalis with a Buy, cites ‘best-in-class infrastructure’ - TipRanks
Guggenheim Initiates Buy Rating for Personalis (PSNL) with $6 Target | PSNL Stock News - GuruFocus
Guggenheim Initiates Personalis at Buy With $6 Price Target - marketscreener.com
Guggenheim Starts Coverage on Personalis (PSNL) with Buy Rating - GuruFocus
Guggenheim Starts Coverage on Personalis (PSNL) with Buy Rating | PSNL Stock News - GuruFocus
Dimensional Fund Advisors LP Purchases 242,141 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Raymond James Financial Inc. Takes Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Leading Genomics Company Personalis Takes Center Stage at Major Craig-Hallum Investor Conference - Stock Titan
Personalis stock price target raised to $9 at H.C. Wainwright By Investing.com - Investing.com Nigeria
What is HC Wainwright’s Estimate for Personalis Q2 Earnings? - Defense World
Personalis reiterates 2025 revenue guidance of $80M-$90M with focus on MRD testing growth - MSN
HC Wainwright Raises Personalis (NASDAQ:PSNL) Price Target to $9.00 - Defense World
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - MSN
Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth - Yahoo Finance
Barclays PLC Acquires 43,900 Shares of Personalis, Inc. (NASDAQ:PSNL) - The AM Reporter
JPMorgan Chase & Co. Has $34,000 Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Barclays PLC Increases Stock Holdings in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis stock price target raised to $9 at H.C. Wainwright - Investing.com Australia
Personalis Inc.: Strong Financial Performance and Promising Future Prospects Drive Buy Rating - TipRanks
Will Personalis' Testing Growth And MRD Strategy Pay Off In 2025? - Nasdaq
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Personalis Inc-Aktie (PSNL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Moore Stephen Michael | SVP and Chief Legal Officer |
May 16 '25 |
Sale |
4.95 |
1,675 |
8,291 |
64,200 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
May 16 '25 |
Sale |
4.95 |
910 |
4,504 |
124,957 |
| Tachibana Aaron | CFO AND COO |
Jan 28 '25 |
Sale |
5.79 |
708 |
4,099 |
166,390 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Jan 28 '25 |
Sale |
5.79 |
519 |
3,005 |
123,367 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Dec 16 '24 |
Sale |
3.82 |
4,834 |
18,466 |
123,886 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
Dec 16 '24 |
Sale |
3.82 |
1,513 |
5,780 |
65,875 |
| Tachibana Aaron | CFO AND COO |
Dec 16 '24 |
Sale |
3.82 |
6,865 |
26,224 |
167,098 |
| Tachibana Aaron | CFO AND COO |
Nov 18 '24 |
Sale |
3.79 |
1,307 |
4,954 |
173,963 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
Nov 18 '24 |
Sale |
3.79 |
1,693 |
6,416 |
67,388 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Nov 18 '24 |
Sale |
3.79 |
921 |
3,491 |
128,720 |
1.52%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):